In this article, we discuss the top 5 stock picks of Henrik Rhenman’s Rhenman Partners. If you want our detailed analysis of Rhenman Partners’ history, investment philosophy, and hedge fund performance, go directly to Top 10 Stock Picks of Henrik Rhenman’s Rhenman Partners.
5. McKesson Corporation (NYSE:MCK)
Rhenman Partners’ Stake Value: $29,082,000
Percentage of Rhenman Partners’ 13F Portfolio: 2.86%
Number of Hedge Fund Holders: 59
McKesson Corporation (NYSE:MCK) offers healthcare services in the United States and worldwide. It operates in four segments: the U.S. Pharmaceutical, Global, Medical-Surgical, and Prescription Technology Solutions (RxTS). The Pharmaceutical segment in the United States distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. Rhenman Partners added McKesson Corporation (NYSE:MCK) to its Q1 2022 portfolio by acquiring 95,000 shares worth $29.08 million, representing 2.86% of the total holdings.
On July 25, McKesson Corporation (NYSE:MCK) declared a $0.54 per share quarterly dividend, a 14.9% increase from its prior dividend of $0.47. The dividend is payable on October 3, to shareholders of record as of September 1.
4. UnitedHealth Group Inc. (NYSE:UNH)
Rhenman Partners’ Stake Value: $29,578,000
Percentage of Rhenman Partners’ 13F Portfolio: 2.91%
Number of Hedge Fund Holders: 103
UnitedHealth Group Inc. (NYSE:UNH) is a diversified US healthcare company. It operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and OptumRx. Rhenman Partners, as of Q1 2022, owns 58,000 shares of UnitedHealth Group Inc. (NYSE:UNH), worth $29.5 million, representing 2.91% of the total 13F holdings.
Argus analyst David Toung on July 25 raised the firm’s price target on UnitedHealth Group Inc. (NYSE:UNH) from $580 to $650 and maintained a Buy rating on the stock following its Q2 results and guidance increase.
3. AbbVie Inc. (NYSE:ABBV)
Rhenman Partners’ Stake Value: $31,611,000
Percentage of Rhenman Partners’ 13F Portfolio: 3.11%
Number of Hedge Fund Holders: 76
AbbVie Inc. (NYSE:ABBV) is a pharmaceutical company that discovers, develops, manufactures, and sells pharmaceuticals worldwide.
Securities filings for Q1 2022 reveal that Rhenman Partners added AbbVie Inc. (NYSE:ABBV) to its portfolio by purchasing 195,000 shares worth $31.6 million, representing 3.11% of the total 13F holdings.
2. Horizon Therapeutics Public Limited Company (NASDAQ:HZNP)
Rhenman Partners’ Stake Value: $35,333,000
Percentage of Rhenman Partners’ 13F Portfolio: 3.48%
Number of Hedge Fund Holders: 56
Horizon Therapeutics Public Limited Company (NASDAQ:HZNP), a biotechnology firm, is dedicated to the discovery, development, and commercialization of medicines that address the critical needs of people affected by rare, autoimmune, and severe inflammatory diseases. The company is divided into two divisions: Orphan and Inflammation. Its product portfolio includes 12 medicines for rare diseases, gout, ophthalmology, and inflammation. Rhenman Partners added Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) to its Q1 portfolio by buying 335,837 shares worth $35.33 million, representing 3.48% of the total holdings.
Here is what Carillon Tower Advisers has to say about Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) in their Q1 2021 investor letter:
“Horizon Therapeutics is a biopharmaceutical company whose primary focus is research, development, and marketing late-stage pharmaceutical products. After experiencing some unfortunate manufacturing hiccups in the later stages of 2020 for its key product, Tepezza, which is used in treating thyroid eye disease, the company recently received positive news that should relieve their supply issues going forward. With the manufacturing of Tepezza back online after being forced to halt due to Operation Warp Speed’s COVID-19 vaccine production orders, Horizon expects patient treatments to resume in mid-April.”
1. Eli Lilly and Company (NYSE:LLY)
Rhenman Partners’ Stake Value: $35,367 ,000
Percentage of Rhenman Partners’ 13F Portfolio: 3.48%
Number of Hedge Fund Holders: 53
Eli Lilly and Company (NYSE:LLY) discovers, develops, and sells human pharmaceuticals worldwide.
Rhenman Partners purchased 123,500 shares of Eli Lilly and Company (NYSE:LLY) in Q1 2022, worth $35.3 million, representing 3.48% of the total 13F portfolio.
Eli Lilly and Company (NYSE:LLY) was discussed in the Q1 2022 investor letter of Baron Funds. Here’s what the firm said:
“Eli Lilly and Company (NYSE:LLY) is a global pharmaceutical company with a diverse offering primarily focused on therapeutics. Performance was strong mostly due to consistent financial growth powered by its core diabetes (and future obesity) franchise, as well as the constant drumbeat surrounding the Alzheimer’s therapeutic market, of which Eli Lilly has one of the three potential winning blockbuster candidates in Donanemab. We retain conviction in Eli Lilly given the company’s strong long-term growth outlook.”
You can also look at Top 10 Stock Picks of Minerva Advisors and Top 10 Marijuana Stocks to Invest In Right Now.
